At present, the CheckMate 816 regimen has received regulatory approval, among others, from the European Medicines Agency (EMA; for patients with tumour PD-L1 ⩾1%) and the Food and Drug Association (FDA) in the United States (irrespective of tumour PD-L1 expression). Here, CD274 is linked to neoplasm.